8-K: MaxCyte Lowers 2025 Guidance Amid Q2 Revenue Drop

MaxCyte, Inc. reported an 18% decrease in total revenue for Q2 2025 and lowered its full-year 2025 guidance due to customer inventory management and pipeline reprioritization.

Summary

• Total revenue for the second quarter of 2025 was $8.5 million, an 18% decrease compared to $10.4 million in Q2 2024.
• Core business revenue increased by 8% to $8.2 million in Q2 2025 from $7.6 million in Q2 2024.
• Strategic Platform License (SPL) Program-related revenue significantly decreased by 89% to $0.3 million in Q2 2025 from $2.9 million in Q2 2024.
• Gross profit for Q2 2025 was $7.0 million (82% gross margin), down from $8.9 million (86% gross margin) in Q2 2024.
• Net loss for Q2 2025 was $12.4 million, compared to a net loss of $9.4 million for the same period in 2024.
• EBITDA loss for Q2 2025 was $13.1 million, compared to a loss of $10.9 million in Q2 2024.
• Cash, cash equivalents, and investments totaled $165.2 million as of June 30, 2025, including approximately $7.0 million in costs for the SeQure Dx acquisition.
• MaxCyte added two new SPL clients, Adicet Bio and Anocca AB, in July, bringing the total number of SPL agreements to 31.
• The company updated its 2025 guidance, expecting core revenue to be flat to a 10% decline compared to 2024, and SPL Program-related revenue to be approximately $5 million for the year.
• MaxCyte anticipates ending 2025 with at least $155 million in total cash, cash equivalents, and investments.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant drop in total revenue, increased net loss, and lowered full-year guidance, which indicates short-term headwinds. However, the underlying core business growth, addition of new SPL clients, and strong cash position with a stated path to profitability using existing capital provide some resilience and long-term potential, preventing a lower score.

Positives

• Core business revenue increased by 8% to $8.2 million in Q2 2025, demonstrating underlying growth in instrument, PAs, consumables, and license sales.
• Two new Strategic Platform License (SPL) clients, Adicet Bio and Anocca AB, were added in July, expanding the total SPL agreements to 31.
• The company maintains a strong cash position with $165.2 million in cash, cash equivalents, and investments as of June 30, 2025.
• Management expressed confidence in achieving profitability with existing capital, indicating financial stability and a clear path forward.
• The installed base of instruments grew to 814 as of June 30, 2025, up from 723 in Q2 2024, reflecting continued adoption of the technology.
• Non-GAAP adjusted gross margin improved slightly to 83% in Q2 2025 from 82% in Q2 2024, excluding SPL Program-related revenue and inventory reserves.

Negatives

• Total revenue decreased by 18% to $8.5 million in Q2 2025 compared to $10.4 million in Q2 2024.
• SPL Program-related revenue saw a significant 89% decrease to $0.3 million in Q2 2025 from $2.9 million in Q2 2024, attributed to timing variability of milestones and royalties.
• Net loss increased to $12.4 million in Q2 2025 from $9.4 million in Q2 2024.
• EBITDA loss widened to $13.1 million in Q2 2025 from $10.9 million in Q2 2024.
• Full-year 2025 guidance for core revenue was lowered to flat to a 10% decline compared to 2024.
• Full-year 2025 guidance for SPL Program-related revenue was lowered to approximately $5 million.
• Operating expenses increased slightly to $21.2 million in Q2 2025 from $20.9 million in Q2 2024.

Risks

• Actual results, performance, or achievements may materially differ from forward-looking statements due to substantial known and unknown risks, uncertainties, and assumptions.
• The company's ability to expand its customer base and enter into additional SPL partnerships may be impacted by market conditions.
• Partners' access to capital markets to develop and commercialize their cell therapy programs is a risk factor.
• The company's financial performance and capital requirements are subject to various uncertainties.
• The adequacy of cash resources and the availability of financing on commercially reasonable terms are not guaranteed.
• The ability to obtain and maintain intellectual property protection for products, as well as operating without infringing the intellectual property rights of others, poses a risk.
• General market and economic conditions may impact investor confidence in the biopharmaceutical industry, affecting capital provided to partners.
• The company's use of available capital resources may not yield expected returns or be sufficient for future needs.

Future Outlook

MaxCyte updated its full-year 2025 guidance, now expecting core revenue to be flat to a 10% decline compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is projected to be approximately $5 million for the year, encompassing both pre-commercial milestone payments and commercial royalties/sales-based payments. The company anticipates ending 2025 with at least $155 million in total cash, cash equivalents, and investments. Management remains confident in achieving profitability with existing capital through improving operational efficiencies, multiple product offerings, and maturing customer clinical programs.

Management Comments

• "Despite solid growth in the first half of 2025, the operating environment has evolved since the beginning of the year, impacting our expectations for the second half of 2025."
• "We are lowering our 2025 guidance to account for customer inventory management, as well as some reprioritization and consolidation of customer pipelines."
• "While disappointed with the short-term headwinds, we continue to remain focused on executing in this environment, supporting customers with excellent technology and service."
• "Our pipeline of potential SPLs remains strong, demonstrated by the two new SPLs that we recently announced, Adicet Bio and Anocca AB, bringing our total number of SPL agreements to 31."
• "We continue to be confident about the opportunity in the cell and gene therapy industry and our position in it, remaining committed to spending prudently, and investing in product enhancements and SeQure Dx."
• "We are confident that with improving operational efficiencies, multiple product offerings, and maturing clinical programs of our customers, we will achieve profitability with our existing capital."

Industry Context

The cell and gene therapy industry is identified as one of the fastest-growing and most promising treatment modalities, with approximately 1,950 active clinical trials as of December 2024 and $15.2 billion raised in 2024. Despite this growth, the industry faces challenges such as increasing complexity of next-generation cell therapy programs requiring multiple edits, rising regulatory risks with new unknowns, high vein-to-vein manufacturing times, and a lack of industry standards for cell engineering process development. MaxCyte positions its Flow Electroporation technology and SeQure Dx gene editing risk assessment services as solutions to these challenges, enabling precise, efficient, and scalable cell engineering to accelerate the development of safe and effective treatments.

Comparison to Industry Standards

• MaxCyte's platform supports 19 clinical and commercial therapies, including the FDA, European Commission, UK MHRA, and SFDA-approved CASGEVY for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta-Thalassemia (TDT), developed by Vertex Pharmaceuticals and CRISPR Therapeutics.
• The company's SPL portfolio includes 22 active clinical trials across various indications, such as CB010 (NHL) by Caribou Biosciences, Azer-Cel (NHL) by Imugene, Azer-Cel (AID) by TG Therapeutics, KSQ-001EX and KSQ-004EX by KSQ Therapeutics, VIPER-101 by Vittoria Biotherapeutics, WU-CART-007 by Wugen, and CTX112/CTX131 programs by CRISPR Therapeutics.
• MaxCyte's technology is utilized in diverse cell types and approaches (autologous/allogeneic) and gene manipulation technologies, supporting a broad range of therapeutic areas including genetic diseases, solid tumors, hematological malignancies, and autoimmune diseases.
• The company's Flow Electroporation technology offers high performance (>90% transfection efficiencies and cell viabilities) and scalability (transfecting up to 200 billion cells in less than 30 minutes), which are critical for meeting the demands of large-scale cell therapy manufacturing compared to traditional methods.

Stakeholder Impact

• Shareholders may experience negative sentiment and potential share price decline due to lowered guidance and increased net loss, but the long-term growth potential from new SPLs and the robust cell and gene therapy market could offer future upside.
• Customers will continue to receive support with MaxCyte's technology and services, with new SPL clients benefiting from the expanded platform.
• Employees will be impacted by the company's focus on operational efficiencies and prudent spending, while also benefiting from continued investment in product development and the SeQure Dx integration.

Next Steps

• Host a conference call on August 6, 2025, at 4:30 p.m. Eastern Time to discuss financial results.
• Continue to focus on executing in the current operating environment and supporting customers with technology and service.
• Commit to spending prudently and investing in product enhancements and the SeQure Dx acquisition.
• Work towards achieving profitability with existing capital through improving operational efficiencies, multiple product offerings, and maturing customer clinical programs.

Key Dates

Recommendation

While the significant decline in total revenue and the lowered full-year guidance present clear short-term headwinds and indicate a challenging operating environment, the underlying core business revenue growth and the continued expansion of Strategic Platform Licenses (SPLs) demonstrate fundamental strength. The company's strong cash position of $165.2 million and management's stated confidence in achieving profitability with existing capital provide a crucial buffer. Given the mixed signals—short-term disappointment offset by long-term strategic positioning in a high-growth industry—a 'hold' recommendation is appropriate. Investors should monitor the execution of the updated guidance and the progress of SPL programs, particularly the timing of milestone payments, before making further investment decisions.

Keywords

Cell engineering, Gene therapy, Biotechnology, Electroporation, Cell therapeutics, SEC filing, Financial results, Guidance, Strategic Platform License, Biopharma, Life sciences